Test Price
650 AED✅ Home Collection Available
Chemotherapy Pre-Treatment SARS-CoV-2 Screening Profile in UAE | 650 AED | DHA Approved
Executive Summary & Core Metrics
Executive Summary: This DHA-endorsed pre-chemotherapy panel unifies SARS-CoV-2 RT‑PCR detection with a complete blood count (CBC), comprehensive metabolic panel, and inflammatory markers—delivering a same‑platform snapshot of infectious risk and physiological readiness before cytotoxic therapy. The profile is processed in our ISO 9001:2015 accredited laboratory (Cert: INT/EGQ/2509DA/3139) under DHA facility license 1143, with results available in 2 days.
- ✓ Accuracy: 99.9% diagnostic sensitivity via multiplex RT‑PCR targeting ORF1ab, N, and E genes combined with automated hematology and chemistry.
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM, including weekends and public holidays.
- ✓ Clinical Guidance: Complimentary telephonic post‑test result interpretation by a DHA‑licensed physician.
- ✓ Insurance: Direct billing verification via WhatsApp at +971 54 548 8731 (all major UAE insurers accepted).
Test Overview & Methodology
The Chemotherapy Pre-Treatment SARS‑CoV‑2 Screening Profile is a single‑visit diagnostic panel designed for oncology patients who require rapid, definitive exclusion of active COVID‑19 and a baseline haematological/metabolic assessment before initiating or continuing chemotherapy. By combining molecular virology (real‑time PCR) with automated hematology (complete blood count with differential) and clinical chemistry (renal function, liver enzymes, electrolytes, glucose, and high‑sensitivity C‑reactive protein), it eliminates the need for multiple draws and accelerates clinical clearance.
| Feature | Our Comprehensive Profile | Standalone COVID‑19 PCR | Rapid Antigen Test |
|---|---|---|---|
| Diagnostic Precision | Multiplex RT‑PCR (ORF1ab, N, E genes) + hematology & chemistry cross‑validation | Single‑target RT‑PCR | Lateral flow immunochromatography |
| Methodology | Real‑Time PCR, Electrical Impedance/VCS, Indirect ISE, Spectrophotometry, Immunoturbidimetry | Real‑Time PCR only | Visual read immunoassay |
| Turnaround Time | 2 days (sample by 11 AM daily) | 24–48 hours | 15–30 minutes |
| Pre‑Chemotherapy Clearance | Complete; includes absolute neutrophil count, renal/hepatic function, CRP | Virology only; additional blood work required | Not accepted due to low sensitivity |
Physician Insight & Safety Protocols
“As a specialist in diagnostic radiology, I emphasize that this pre‑treatment screening profile provides a critical baseline for safe chemotherapy administration. The integration of multiplex PCR with haematological and biochemical markers allows the oncologist to assess both active infection and end‑organ reserve simultaneously. Results should always be interpreted alongside clinical findings and imaging—laboratory data alone does not dictate therapy decisions.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory Precautions
Medication & Safety Guidance
- Never discontinue prescribed chemotherapy, immunosuppressants, or anticoagulants without explicit oncologist approval. This test is an adjunct to clinical decision‑making, not a substitute.
- Home collection is available for standard peripheral whole blood and nasopharyngeal swab. Emergency red flags such as sudden dyspnoea, chest pain, or oxygen saturation <92% require immediate emergency evaluation.
- Patients with known heparin‑induced thrombocytopenia or latex allergy must inform the mobile phlebotomy team in advance.
Exclusion Criteria for Home Phlebotomy
Conditions Requiring Hospital‑Based Collection
- Active haemorrhage or bleeding diathesis
- Severe thrombocytopenia (<20×10⁹/L)
- Haemodynamic instability or any medical emergency warranting inpatient care
- Patients under isolation due to confirmed infectious disease
Patient FAQ & Clinical Guidance
1. What is included in this profile, and why is it necessary before chemotherapy?
This profile combines a SARS‑CoV‑2 RT‑PCR test with a complete blood count, comprehensive metabolic panel, and high‑sensitivity C‑reactive protein. It provides your oncologist with a single‑report snapshot of COVID‑19 status, bone marrow function, liver and kidney health, and systemic inflammation—all critical factors to safely proceed with chemotherapy. Without this screening, an asymptomatic infection or low neutrophil count could lead to life‑threatening complications during treatment.
2. How is the sample collected, and what quality measures are in place?
A trained phlebotomist collects one serum separator tube, one EDTA whole blood tube, and a nasopharyngeal/oropharyngeal swab in viral transport medium using full personal protective equipment. Samples are transported in an ISO‑certified cold‑chain box (never frozen) and processed within 2 hours of collection to preserve RNA integrity and cellular parameters. The laboratory operates under DHA facility license 1143 at Premises 105, Floor 1, Building 33, Dubai Healthcare City.
3. Can this profile be used after COVID‑19 vaccination or a prior positive PCR?
Yes; this profile detects active viral RNA, not antibodies, so vaccination does not affect the result. If you previously tested positive and are asymptomatic, your oncologist may use the haematological and metabolic data to judge resolution before restarting therapy. Always disclose prior test results and vaccination history to the collection team.
4. What is the turnaround time, and how will I receive results?
Results are reported within 2 calendar days from sample reception (samples arriving by 11 AM are processed the same day). Reports are delivered via secure digital portal and WhatsApp. A DHA‑licensed physician is available for complimentary telephonic interpretation.
5. Is home collection available for all patients?
Yes, VIP Mobile Phlebotomy is available daily from 8 AM to 11 PM for standard peripheral blood and nasopharyngeal swabs. Patients with bleeding disorders, severe thrombocytopenia, or haemodynamic instability must have samples collected in a hospital setting for safety.
UAE Regulatory & Data Privacy Adherence
Your Data, Our Commitment
This service strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient identifiers are pseudonymized during processing and result transmission. Clinical testing safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. The facility is licensed by the Dubai Health Authority (DHA) under license number 1143 and operates at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
A valid Emirates ID and completed DHA‑approved COVID‑19 Clinical Information Form are mandatory at the time of sample collection.
Clinical & Logistical Metadata
| Test Name | Chemotherapy Pre-Treatment SARS-CoV-2 Screening Profile |
| Price (AED) | 650 AED |
| Turnaround Time | 2 days (sample by 11 AM daily) |
| Sample Type / Matrix | Peripheral whole blood (EDTA and serum) + Nasopharyngeal/oropharyngeal swab in viral transport medium |
| Methodology Used | Real-Time PCR, Electrical Impedance/VCS, Indirect ISE, Spectrophotometry, Immunoturbidimetry |
| ICD-10-CM Code | Z11.52, U07.1 (if applicable), D70.9 (if neutropenia detected) |
| LOINC Code | 94500-6 (SARS-CoV-2 RNA PCR), 58410-2 (CBC panel), 24323-2 (Comprehensive metabolic panel) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians